Table 2 Detailed information about treatment protocol and adverse reactions of included studies
Study | Treatment protocol | Adverse reactions | ||
|---|---|---|---|---|
CYC/GCs | Control group | CYC/GCs | Control group | |
Shi 2004 [25] | Retrobulbar injection of DEX 5 mg and CYC 10 mg every week for 10 weeks | Retrobulbar injection of DEX 5 mg every week for 10 weeks | Conjunctival edema; retrobulbar hemorrhage; ptosis | Conjunctival edema; retrobulbar hemorrhage; ptosis |
Liu 2005 [26] | Intravenous MPS 0.5g and CYC 0.2g every week for 4 weeks | Intravenous MPS 0.5g every week for 4 weeks | GCs-related adverse reactions (4 cases); electrolyte disorders (1 case) | GCs-related adverse reactions (8 cases); electrolyte disorders (3 cases) |
Zhang 2005 [22] | Intravenous MPS 1.5g and CYC 0.6g every week for 4 weeks | Negative control | Mild euphoria (3 cases); insomnia (3 cases); stomach discomfort (3 cases) | Mild euphoria (4 cases); insomnia (4 cases); hypokalemia (5 cases); thrombocytopenia (3 cases) |
Ruan 2006 [27] | Retrobulbar injection of DEX 5 mg and CYC 50 mg every week for 10 weeks | Retrobulbar injection of DEX 5 mg every week for 10 weeks | Conjunctival edema; retrobulbar hemorrhage; ptosis | Conjunctival edema; retrobulbar hemorrhage; ptosis |
Tang 2006 [28] | Intravenous CYC 0.8g every week in the first two weeks, oral MPS 0.24g every week in the next two weeks | Negative control | NA | NA |
Su 2014 [29] | Intravenous MPS 0.48g and oral CYC 0.2g each day | Negative control | NA | NA |
Dai 2015 [30] | Intravenous MPS 1g/day for 3 days, then intravenous CYC 2g every month for 3 months | Oral P 60mg/day for 3 months | Elevated blood pressure (3 cases); elevated blood glucose (2 cases); weight gain (6 cases); severe infections (4 cases) | Elevated blood pressure (1 case); elevated blood glucose (5 cases); weight gain (10 cases); severe infections (1 case) |
Wang 2015 [31] | In the first 8 weeks, oral P 60mg/day, and then reducing P dose 15mg/day every week. At 9th week, oral CYC 80mg/day for 8 weeks | Negative control | NA | NA |
Wen 2016 [32] | Intravenous MPS 1.5g and CYC 0.6g every week for 3 weeks | Negative control | NA | NA |
Gao 2018 [33] | Intravenous MPS 1.5g and CYC 0.6g every week for 3 weeks | Negative control | Mild euphoria (3 cases); stomach discomfort (3 cases); insomnia (2 cases) | Nil |
Liang 2020 [34] | Oral CYC 100mg/day for 3 months, intravenous MPS 80mg/week for 3 months | Intravenous MPS 80mg/week for 3 months | Dyspepsia (1 case); stomatitis (1 case); alopecia (1 case) | Nausea (1 case); dyspepsia (1 case) |
Cajal 2020 [35] | Intravenous MPS 0.6g and CYC 0.3g three times a month for 3 months | Intravenous MPS 1g three times a month for 3 months | NA | NA |
Wang 2021 [36] | In the first 5 weeks, oral P 60mg/day, and then reducing P dose 15mg/day every week. At 6th week, oral CYC 100mg/day for 8 weeks | Negative control | NA | NA |